Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Baxter
US Department of Justice
McKinsey
Queensland Health

Generated: September 17, 2019

DrugPatentWatch Database Preview

Patent: 7,361,740

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,361,740
Title:Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
Inventor(s): Hinton; Paul R. (Sunnyvale, CA), Tsurushita; Naoya (Palo Alto, CA), Tso; J. Yun (Menlo Park, CA), Vasquez; Maximiliano (Palo Alto, CA)
Assignee: PDL BioPharma, Inc. (Redwood City, CA)
Application Number:10/822,300
Patent Claims:see list of patent claims

Details for Patent 7,361,740

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2016-05-27 ➤ Sign Up PDL BioPharma, Inc. (Redwood City, CA) 2022-10-15 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
US Department of Justice
Farmers Insurance
AstraZeneca
Fuji
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.